Chad Landmon chairs Polsinelli’s Hatch-Waxman & Biologics Practice and is a first chair trial lawyer known for helping life sciences and healthcare companies navigate complex patent litigation, Food and Drug Administration (FDA) regulatory challenges and Administrative Procedure Act (APA) proceedings. He represents pharmaceutical, biologics, medical device and human tissue product companies, helping them efficiently and profitably bring products to market while protecting critical commercial interests.

Beyond his primary Hatch-Waxman and biologics litigation focus, Chad manages matters at the intersection of patent, regulatory, administrative and antitrust law. He has significant experience litigating matters that affect competition, exclusivity rights and market access, including those arising under the Hatch-Waxman Act, the Biologics Price Competition and Innovation Act and related FDA regulatory frameworks. He also manages matters involving patent settlements, exclusivity controversies and other litigation affecting the life sciences and health care industries.

Chad's practice combines first-chair litigation experience with a deep understanding of FDA regulatory framework and federal administrative processes. In addition to serving as lead trial counsel in Hatch-Waxman and biologics patent disputes, he co-chairs the APA Practice Group and represents clients in FDA citizen petitions, APA challenges and other matters involving marketing exclusivities, patent listings, bioequivalence determinations, labeling requirements, product approvals and related agency actions. He also advises clients on preserving rights throughout the administrative process and developing regulatory strategies that support successful litigation outcomes when agency decisions threaten critical business objectives.

He is recognized globally as a leading patent litigator by IAM Patent 1000, Benchmark Litigation and Law360. Over the past decade, he has successfully litigated over 60 cases and represented companies whose products generate billions of dollars in annual sales. His notable achievements include leading a groundbreaking case in which a court mandated the FDA to approve a product, a benchmark case covered extensively by the media. Recognized as a "Life Sciences Star" by LMG Life Sciences and a "Health Care/Life Sciences Trailblazer" by The National Law Journal, Chad has advised on nine of the top 10 generic drugs by cost savings and nearly half of the top 100 by sales volume.

Chad frequently speaks and writes about an array of issues relating to litigation in the life sciences industry, including skinny label litigation, the U.S. regulatory landscape and cell and gene therapies. He was active in local government in Southbury, Connecticut, for nearly a decade, including serving as an elected member of their Board of Selectmen. Additionally, Chad is a strong supporter of charity: water, a nonprofit that brings clean water to communities around the world.